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Abstract
The Effects of Bisphosphonates on Bone Remodeling: Analysis of Microdamage Targeting by
BMUs, BMU Velocity and Crack Surface Density
By Daniel Wayne Hale

Studies have indicated that microdamage in the bone matrix both activates and "steers"
BMUs (Basic Multicellular Units, the groups of osteoclasts and osteoblasts that resorb and form
bone respectively) toward the damage in order to replace damaged bone with new, mechanically
sound bone. Also, bisphosphonate drugs have been shown to greatly suppress the remodeling
process and, with such effects, are commonly used in the treatment of osteoporosis. It was
hypothesized that BMUs do indeed target microdamage around them and tunnel away from the
dominant lines of force in bone in order to remove the damage. Additionally it was believed that
bisphosphonates would have a suppressive force on the BMU's ability to seek out and remove
microdamage. This study explored a further hypothesis that bisphosphonates would decrease
BMU velocity and osteonal area while increasing crack surface density in a dose-dependent
manner. Thirty-six rib bone samples were obtained from the Indiana University School of
Medicine from a three year canine study in which skeletally mature beagles were administered
the bisphosphonate Alendronate in doses matching, on a body weight basis, those used to treat
postmenopausal osteoporosis. Control, clinical dose (Alendronate 0.2 mg/kg body weight), and
five times clinical dose (Alendronate 1.0 mglkg body weight) treatment groups were created with
12 dogs in each group. Before harvesting rib bones, the dogs were injected with calcein at two
different time periods to mark areas of new bone formation. For this study, data for mean crack
length, resorption space density, osteonal area, and crack surface density were obtained from
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Matt Allen at the Indiana University School of Medicine. BMU velocity was determined by
measuring the distance between fluorescent labels in longitudinal sections of bone and dividing
by the time between injections. Statistical analysis supported the hypothesis that BMUs target
microdamage and bisphosphonates suppress that ability in a dose dependent manner. Also,
bisphosphonates have a significant suppressive effect on BMU velocity. Analysis shows that
there is no difference in osteonal area or crack surface density among the three treatment groups
(CON, ALNO.2, and ALNI.O) leading to the conclusion that bisphosphonates seemed to have
little effect on osteonal area or crack surface density over the three year study.
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1.

Introduction and Literature Review

Bone Tissue
The skeletal system of the human body is a highly adaptable and constantly changing
structure. Bone density is under continuous optimization to produce the highest strength with the
lowest amount of weight. There are two main types of bone, called compact (cortical) bone and
trabecular (cancellus) bone respectively, which comprise a majority of the long bones that make
up the skeleton (Figure 1).
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Figure 1. Important features of a typical long bone including compact and trabecular bone (1)

Compact bone resides as the outer layer of a bone and is characterized by circular structures
called osteons (Figure 2).
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Figure 2. Osteons in compact bone (1)

A blood vessel runs through the central canal of each osteon, called a Haversian canal, and is
responsible for providing nutrients and removing wastes from the surrounding bone cells [1].
Compact bone has a high fracture resistance and toughness due to the geometry of the osteon.
Osteons are built up as oppositely oriented, concentric, circular matrices called lamellae. This
geometry provides a high level of fracture resistance since the energy of approaching cracks is
dissipated around the edge of the circular osteon. As the forces acting on an osteon increases, the
circular layers begin to pull apart and delaminate before they begin to crack. A large amount of
the energy contained in a crack is dissipated as an osteon "unravels". This behavior gives cortical
bone a facture toughness of2.2-6.3 MPa-m ll2 , elastic modulus of 17.4 GPa, and a high tensile
ultimate stress of 133 MPa [1]. Trabecular bone is found near the ends of long bones and is
characterized by a sponge-like geometry with many interconnected struts (Figure 3).
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Figure 3. Trabecular bone structure (I)

Trabecular bone is specialized for absorbing and dissipating the energy of impact on bone. The
geometry of trabecular bone is optimized to support large loads and spread forces acting on
bones. Due to their geometry, trabecular bone has an elastic modulus of 272 ± 195 MPa and an
ultimate stress of2.54 ± 0.62 MPa [1]. Through the center of long bones runs the medullary
canal. This area is filled with bone marrow which contains undifferentiated stem cells that form
components of the immune system, red blood cells, and bone cells.

Bone Cells
The arbitrators of bone turnover are osteonal bone cells; primarily osteoclasts,
osteoblasts, osteocytes, and bone lining cells. Osteoclasts are multinucleated cells originating in
the bone marrow. They arise from the fusion of multiple differentiating bone marrow cells. Their
main function is to absorb bone through the use of enzymes. Existing bone is absorbed at the
interface between the cellular membrane and the bone surface (brush border) created by
numerous infoldings of the osteoclasts' plasma membrane [1] (Figure 4).
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Figure 4. Multinuclear osteoclast (upper right) resorbing bone (lower left). CZ labels clear zones where the cell is
sealed to the bone surface; RB labels the ruffled border where enzymes are released to break down bone; B labels
the calcified bone matrix. (1)

Enzymes are released at the brush border that de-mineralize the bone matrix and then dissolve
the bare collagen scaffold. In this way osteoclasts are similar to macrophages in that they absorb
and consume bone. Osteoblasts are mononucleated cells that originate in the bone marrow.
Growth factors influence the differentiation of bone marrow progenitor cells into osteoblasts [1].
Their main function is to generate osteoid tissue (un-mineralized matrix of Type I collagen) as
they foHow bone absorbing osteoclasts (Figure 5).

4

Figure 5. Osteoblast forming bone. The dark area at the bottom is mineralized bone. Lighter material is osteoid
produced by the rough endoplasmic reticulum of the cell. A portion of a process of the cell protrudes into the lighter
osteoid material. (I)

Osteoblast activation is contingent on osteoclast activation and their relative activities may be
linked or unlinked. As more osteoid tissue is produced, osteoblasts become trapped in the
developing matrix and become osteocytes. Osteocytes are connected to other osteocytes in the
bone matrix through channels called canaliculi. Cytoplasmic processes of neighboring osteocytes
form gap junctions through which nutrients and chemical signals can pass [1]. The network of
communication between osteocytes is called the syncytium. Through this network, osteocytes
can relay information governing apoptosis, increasing forces, and nutrient deprivation. Bone
lining cells are present on the periosteal and endosteal surfaces of bone and arise from

5

osteoblasts on the surface of bone. They lie in a layer and regulate the movement of calcium and
phosphate into and out of bone. Also, bone lining cells communicate with osteocytes and receive
signals in response to high stress levels in the bone matrix. Upon signaling, the cells release
honnones that activate complacent osteoclasts and migrate from the bone surface to expose bone
to active osteoclasts. In this way bone lining cells playa role in the modulation of the remodeling
process. Bone lining cells are thought to inhibit reabsorption of bone as long as they cover the
bone surface. The cellular unit involved in bone resorption and fonnation is called the Basic
Multicellular Unit (BMU) (Figure 6).

Figure 6. BMU. Two multinuclear osteoclasts are visible on the right; osteoblasts are on bone surfaces on the left.
(1)

A BMU is composed of osteoclasts that are responsible for bone absorption followed by
osteoblasts that deposit the caliginous bone matrix. The osteoclasts fonn a cutting cone at the
head of a BMU that creates a scalloped geometry in the bone matrix as the BMU tunnels. Behind
the osteoclasts, osteoblasts fonn new bone in the open resorption space (Figure 7).
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Figure 7. Osteoclasts (on the right) form the cutting cone of the BMU while osteoblasts (on the left) form new bone
in the space created by the osteoclasts. BMU is traveling to the right. (1)

BMUs travel longitudinally through bone at a rate of 19.18 ± 8.25 /lm a day and are responsible
for creating the osteonal structure of compact bone. Other studies have measured BMU velocities
at about 40 /lm a day [1].

Modeling and Remodeling
Bone turnover can be classified as two different processes: modeling and remodeling.
During modeling, bone resorption and bone formation are unconnected and the overall
morphology and shape of bone is changed. Remodeling links the actions of bone resorption and
formation so that the morphology is unchanged while maintaining the mechanical integrity of
bone. In remodeling, bone formation is preceded by bone resorption and the process keeps bone
in constant state of homeostasis. The cellular unit of remodeling is the BMU
Bone modeling occurs during childhood growth and allows for the "custornization" of a
bone's shape with respect to the loading conditions acting on it (I]. As previously stated,
modeling utilizes the disconnected processes of bone resorption and formation. During childhood
growth, bones increase in length but also need to be modified to the correct geometry to support
the loads placed on the skeleton. Bone may be removed or added in various locations to achieve
optimal bone geometry. One example of modeling occurs in the metaphysis of bones, where
bone is removed by osteoclasts to reduce bone diameter. In areas such as the proximal tibia, a
widely flaring metaphysis is required so osteoclasts resorb bone on the periosteal surface of the
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metaphysis to cut the shaft of bone direction under the growth plate down to size [I]. Another
example of modeling is the adjustment of the curvature of bones during growth. Specific bones
require a certain degree of curvature which is achieved by bone removal and formation on
different sides of bone such that the cross-section "drifts" sideways relative to the ends of the
bone [1]. The modeling process drastically decreases once skeletal maturity is reached while
remodeling continues throughout life and becomes the main process through which bone is
altered.
Remodeling can be initiated by increased forces and loads acting on bones. One theory of
remodeling is that bone lining cells, located on the surface of bone, sense stress and strain during
bone loading and communicate the increase in forces to osteocytes. Osteocytes in the location of
increasing forces recruit osteoc1asts to begin bone resorption at a specific location. Osteoclasts
then begin to absorb bone following the major lines of force (stress and strain) followed by
increased bone formation by osteoblasts. The increased forces on bone guide the osteoclasts by
activating osteocytes present in the bone matrix which then signal to osteoclasts to begin bone
resorption. In this way, bone is built up along the principle stress directions altering the bone's
morphology.
Remodeling is also believed to be initiated by the activity of osteocytes [1, 2, 4]. In this
case, remodeling initiation relies on fractures and crack propagation in the bone matrix.
Osteocytes are either disturbed by propagating cracks or sense the changes in stress distribution
around them [1, 4, 5]. When a crack is formed, osteocytes in the area surrounding the crack
undergo apoptosis and release a multitude of chemical signals as they die. A network of
apoptotic osteocytes forms around the damaged bone and this network attracts active BMUs. The
recruited osteoclasts begin to absorb bone in the area containing the cracks and fractures,

8

ultimately removing a majority of those structures from the bone matrix. Following the
resorption performed by osteoclasts, osteoblasts deposit bone in the newly created cavity. As
osteoblasts continue to generate osteoid tissue they become trapped in the bone matrix and
become osteocytes. In this way, old, weak bone is replaced with new, mechanically sound bone
complete with a syncytium of interconnected osteocytes.
Another activator of the remodeling process is when bone is in a state of disuse. In this
case, bone experiences a low mechanical stress environment and BMU initiation occurs to
remove unneeded bone. The skeletal system, like the rest of the body, attempts to operate at the
highest efficiency possible and will remove metabolically demanding yet mechanically
unnecessary bone.
The process of bone remodeling can be divided into six stages. The first stage is called
the activation stage and it involves the recruitment of osteoclasts from precursor cells. Progenitor
cells in bone are triggered to become osteoclasts and gather at a specific area to form the
resorption cone or cutting cone of the BMU. The next stage ofremodeling is called the

resorption stage. Newly created osteoclasts begin to resorb bone by traveling longitudinally at a
rate of 19.18 ± 8.25 /lm a day. Other studies have measured BMU velocities at approximately 40
jJ.m a day [1]. The area of resorption is an ellipsoidal shape with an approximate diameter of 200
!lm. This diameter can vary between different BMUs. The third stage is called the reversal stage.

In this stage the transition from osteoclastic bone resorption to osteoblastic bone formation takes
place. The length of this stage is dependent on the lag time between osteoclast activation and
osteoblast activation. Typically, the reversal and resorption stages together take about 30 days in
humans. In a completed secondary osteon the cement line is called the reversal line because it
denotes where bone formation began to take place in the BMU. The cement line is the boundary
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around an osteon that separates the newly formed bone of the osteon and the surrounding, older
bone. The fourth stage of bone remodeling is called the/ormation stage. In this stage, osteoblasts
around the outer edge of the tunnel formed by osteoclasts begin to create the collagenous
framework that bone is built upon. Osteoblasts build concentric lamellae at a rate of about 1-2
flm per day [1]. As the tunnel is filled, bone formation slows and a canal is left in the center of
the tunnel. This central area, called a Haversian canal, is approximately 40-50 11m in diameter
and contains an arterial blood vessel. The Haversian canal is necessary because osteoblasts and
osteoclasts are living cells and need nutrients and a waste disposal system. Also, the blood vessel
brings phosphate and calcium ions where they are needed in the bone matrix and provides
nourishment for osteocytes. The next phase is called the mineralization stage and follows the
formation of bone. Up to this point in the remodeling process, organic, unmineralized osteoid
tissue is laid down. Within the first few days after the osteoid tissue is formed approximately
60% of the matrix is mineralized with hydroxyapetite [I]. This stage of mineralization happens
quickly and is called primary mineralization. Secondary mineralization occurs for the next six
months and mineralizes the remaining osteonal tissue. Because of the drawn out mineralization
process, osteons comprised of new bone display different mechanical properties than osteons
made up of older bone. The last phase of the remodeling process is called the quiescence stage.
Once the bone resorption and formation processes are fmished, the BMU "disbands" and
osteoclasts and osteoblasts separate. Approximately 10-20% of the osteoblasts involved in the
BMU transitioned into osteocytes while some become bone lining cells in the Haversian canal
and others disappear entirely [6]. Osteoclasts leave the completed osteon and may join another
BMU. This stage represents the normal activity of an osteon as it functions as a component of the
bone matrix.
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Osteoporosis
The process of bone replacement is fundamental in many life functions. Fracture healing
is a major occurrence that initiates both bone modeling and remodeling. At the crux of
osteoporosis lies a malfunctioning case of bone remodeling. Osteoporosis commonly affects
postmenopausal women over the age of 50 [7]. The disease is characterized by the increasing
porosity of bone and a decrease in bone's fracture toughness. As bone is remodeled, less bone is
deposited after the resorption phase [7]. Osteoblasts exhibit decreased functionality while
osteoclasts continue to function normally. This uneven activity causes the amount of bone
present to continually decrease. Decreasing bone integrity is also seen in older individuals
without osteoporosis. As people age, the number of active BMUs decreases and damage begins
to accumulate [7]. Fracture risk increases due to decreases in the elastic modulus and toughness
of bone and the increase of microdamage [I, 7]. Older individuals experience increasing levels of
bone degeneration and daily activities are impacted.
Current treatment for osteoporosis includes supplementing the diet with vitamin D and
calcium [7, 8]. Increasing specific vitamins and minerals in the diet helps to decrease bone loss
by providing a wealth of available building blocks for bone. Another treatment method involves
exercise utilizing resistance training. Exercise with weights increases the loading on bones and
stimulates the modeling and remodeling processes to increase bone density. Care must be taken
by individuals to avoid injury during weight training. A further method of treating osteoporosis
involves the use of nitrogen-containing bisphosphonate dmgs [8].
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Bisphosphonates
The bisphosphonate class of drugs penetrates the bone matrix and contains chemical
functional groups that inactivate, disrupt, and kill osteoclasts. Decreasing the action of
osteoclasts also reduces the processes of bone resorption and bone fonnation. Initially after
treatment with bisphosphonates, an overall increase in bone density is witnessed as the
osteoblasts that were previously functioning continue to deposit bone [8]. The tradeoff to
bisphosphonate use is that microdamage is allowed to accumulate in the bone structure due to the
reduction of the remodeling process. Recall that remodeling replaces old, damaged bone with
new, mechanically sound bone. As microdamage accumulates, the risk for fracture may increase
as well. Alendronate, a common nitrogen-containing bisphosphonate, is given as osteoporosis
medication under the commercial name Fosamax.
Nitrogen-containing bisphosphonates have a strong affmity for bone and not for other
tissues due to their chemical makeup. Bisphosphonates have a characteristic structure seen in
Figure 8.

H

oII 0I oII
HO-P-C P-OH
I
I
I
o R a
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H

Figure 8. Characteristic structure of bisphosphonates. All have a hydroxyl group on the carbon atom and vary only
at the R group, which always contains a nitrogen atom. (8)

Bisphosphonates have a similar chemical structure to pyrophosphate which accounts for their
attraction to calcium ions. The hydroxyl group on the central carbon atom provides a high
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affinity for calcium circulating in the blood and at the bone surface. Also, the phosphorus
carbon-phosphorus backbone is highly resistant to biological enzymes that usually degrade
foreign chemicals [8]. Bisphosphonates are metabolically inactive which allows them to circulate
the blood stream and exit the body as the original molecule. Variation between bisphosphonates
occurs at the R group attached to the carbon atom which always contains a nitrogen atom in
either an alkyl or heterocydic structure [8].
Nitrogen-containing bisphosphonates work by interfering with the enzymes utilized by
osteoclasts during differentiation and bone absorption. Specifically, bisphosphonates inhibit
famesyl diphosphate synthesis (FPP synthase) [8]. FFP synthases is a crucial part of the
metabolic pathway that activates small GTPases such as Rab, Rac, Ras, and Rho. These GTPases
are signaling proteins that when activated regulate important processes and structural properties
for osteoclast function, including morphology, cytoskeletal arrangement, vesicular trafficking,
and membrane ruffling [8]. Vesicular trafficking and membrane ruffling are two main osteoclast
functions that are essential to bone resorption. The ruffled border produced by osteoclasts at the
bone surface is the site of demineralization and disintegration of the collagen matrix. A
disruption in osteoclasts' vesicular movement means that the enzymes required for bone
degradation will not be concentrated at the bone surface and thus will be ineffective. Also, the
formation of an inadequate ruffled border will inhibit the ability of osteoclasts to resorb bone and
may dislodge them from the bone surface [8]. The concentration ofbisphosphonate medication
given also plays a role in the degree of osteoclast activity suppression. Low concentrations
inhibit the functional osteoclastic activities that involve the cytoskeleton such as vesicular
trafficking and membrane ruffling [8]. Higher concentrations inhibit osteoclast differentiation
and at concentrations nearing 100

~M

osteoclast apoptosis is induced [8]. The majority of BMU
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suppression occurs during the first few months ofbisphosphonate treatment. In a study by
Kimmel [8], osteoclast function was seen to decrease by 70-80% during the first months of
treatment and then remain at that level for the entirety of the treatment. Once bisphosphonate
treatment is stopped, the bone resorption rate increases back to pre-treatment levels.
The pharmacokinetics of nitrogen-containing bisphosphonates focuses on the drug's
interaction with body systems. Upon oral administration of the drug, bisphosphonates begin to
circulate in the bloodstream within a few hours. The drug is then partitioned, approximately
equally, to the kidneys and skeletal system [8].The hydroxyl group contained on the
bisphosphonate has equal affinity for calcium ions circulating the blood and found on the bone
surface. Bisphosphonates reaching the kidneys are eliminated from the body un-metabolized
through the urine whereas the remainder of the drug is deposited to a certain extent on the
skeleton.
Different skeletal areas show different affinities for nitrogen-containing bisphosphonates
depending on the bone-remodeling activity occurring at the bone surface. The three bone regions
to be discussed are resting, resorbing, and forming which are associated with the cellular activity
of bone lining cells, osteoclasts, and osteoblasts respectively. At the resting surfaces, bone is
covered with bone lining cells and thus has a relatively low affinity and retention rate for
bisphosphonates [8]. Since the nitrogen-containing bisphosphonates are bound loosely there is a
chemical gradient that favors their re-uptake into the vascular system within hours to days [8]. A
large portion of bisphosphonates are processed through the resting surfaces due to the large area
of bone classified as resting. The resorbing surfaces make up a smaller p0l1ion of the total bone
surface area but process a large amount ofbisphosphonates because calcium is being released
from the bone surface into the bone fluids by the activity of osteoclasts. Osteoclasts liberate

14

calcium ions as they dissolve the bone matrix and produce a high local concentration of calcium
that is available for chelating by bisphosphonates. As more bisphosphonates are attracted to the
areas of bone resorption, the concentration ofbisphosphonates at these surfaces increases to
levels sufficient to deactivate osteoclast functions [8]. Once FFP synthase is inhibited, the
osteoclasts cease functioning. Ifbisphosphonate treatment is halted the concentration of
bisphosphonates at the resorbing surfaces will be removed within days to weeks ultimately
reaching full removal to the blood and then the kidneys [8]. Forming surfaces have a high
affinity for bisphosphonates too due to the high levels of calcium being affixed to osteoid tissue
during mineralization. All the bisphosphonate at forming surfaces chelates with calcium ions and
is then buried in the bone matrix [8]. The bisphosphonates will remain in the bone matrix until
they are uncovered by resorbing osteoclasts and released into the bone fluid which circulates
back into the bloodstream. Nitrogen-containing bisphosphonates buried in the bone matrix are
considered biologically inert and have no interaction with any bone cells [8]. When
bisphosphonates are released by resorbing BMUs they return to the bloodstream and are equally
partitioned to the kidneys and skeletal system. In this way, bisphosphonates released from the
bone matrix are able to affect osteoclast function, albeit at lower concentrations than the previous
dose. Bisphosphonates uncovered during the remodeling process may also affect osteoclast
function if their local concentration around the osteoclasts is high enough to disrupt FPP
synthase [8].
Even though bisphosphonates specifically target bone tissue and are metabolically
inactive, there are some side effects associated with their use. Acute inflammation of the
esophagus and stomach lining is the most prevalent, yet easy to prevent side effect seen with
bisphosphonate use. Standing or sitting for 30-60 minutes after orally taking the medication is
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enough to avoid stomach and esophageal ilTitation. Another side effect is hypocalcemia or
decreased blood calcium levels. This disease arises due to bisphosphonates' high affinity for
calcium ions. Bisphosphonates circulating in the blood chelate calcium and render it unavailable
for other functional uses. In some cases ofbisphosphonate use renal impairment occurs due to
the drugs passage through the kidneys as it is excreted.

Microdamage Targeting by BMUs
As previously mentioned, BMUs are initiated by cracks and damage within bone (Figure
9).

Figure 9. Microcracks in compact bone. Arrows point to cracks formed between osteoos. (1)

This damage is caused by normal, everyday activities including walking and lifting objects. One
theory is that BMUs reabsorb and deposit bone along the lines of force within bone. Another
theory involving BMU movement during remodeling is that reabsorbing osteoclasts target
microdamage within bone and shift their movement toward damaged areas [2]. Once the
damaged bone has been reabsorbed, the BMU tracks back to the nearest dominant line of force in
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the bone. In this way, bone is strengthened as cells deposit bone along the prominent lines of
force and repair cracks and damage within bone.
Studies proposed that osteonal BMUs tunnel in alignment with the local principal stress
directions [9]. The reasons for this are as follows. Osteocytes need a stress-driven fluid flow
across their processes to survive and remain active [9]. In the absence of a sufficient stress field
osteocytes become apoptotic and release a variety of signaling hormones to surrounding
osteocytes and bone lining cells. These messenger chemicals are a combination of "come eat
me" and "death announcement" signals that attract nearby osteoclasts and communicate with
nearby osteocytes [2]. When BMUs are aligned with the principle stress directions, a region of
very low stress is created slightly ahead of the BMU. This low stress region causes apoptosis of
nearby osteocytes which then release the signaling chemicals to osteoclasts. The BMUs
osteoclasts follow the changes in load direction as the apoptotic signal shifts. In this way the
BMU stays aligned with the dominant stress directions in the bone.
Focusing on BMU activation and steering by microcracks, remodeling activities and
BMU movement will be discussed. It can be assumed that a resorbing BMU will remove at least
a portion of the crack that initiated it and potentially, portions of other cracks encountered during
its movement. Even though only a portion of the crack will be removed, this is extremely
beneficial in reducing the probability of crack extension because the stress required to propagate
a crack is inversely proportional to the square root of its length [10]. With this assumption in
place, the value of microcrack "targeting" in reducing fracture risk is apparent. In a study
performed by Martin, mean microcrack lengths were plotted as a function of resorption space
density for a group of male and female human femur specimens to calculate the average cross
sectional area of a BMU [2]. The value calculated for average cross-sectional area of a BMU was
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2

1.66x10 6 flm which correlates to an osteonal diameter of 1400 flm (assuming circular osteons)
[2]. This value is much larger than osteonal diameters found for human femurs by Moyle and
Bowden [11] which ranged from 150 to 220 flm. An osteonal diameter of 220 flm corresponds to
2

6

2

an osteonal area ofO.038xl0 6 flm which is only 2.3% of 1.66xl0 flm . From these calculations
it can be observed that BMUs are resorbing bone as if they were much larger than they really are.
Martin's calculations represented an "effective BMU area" and not the actual BMU area [2]. The
effective area surrounding the trajectory of a BMU provides a region through which the BMU
can steer in order to remove microdamage.
Martin [2] discussed the possibility of a larger effective BMU area by focusing on two
questions:
I)

How do a BMU's osteoclasts sense microdamage through several hundred)..tm
of intervening bone matrix and direct their resorption toward it?

2)

When signals for steering toward microdamage and steering in alignment with
principle stress direction compete, how are they integrated or resolved?

In response to the first question, focus is placed on the signaling molecules Bax and Bcl-2. Bax
is a molecule commonly expressed in cells undergoing apoptosis [2]. Bcl-2 is a molecule with a
chemical structure similar to Bax but with the function of aiding in cell survival. Due to their
similar chemical structure, Bax and Bcl-2 can form homodimers and heterodimers that play
important roles in regulating osteocyte apoptosis. Homodimers of the Bax molecule result in
mitochondrial structures that produce apoptosis and heterodimers of Bax and Bcl-2 protect
against apoptosis [2]. The following figure, generated by Verborgt et a1. [4], shows the
distribution of cells exhibiting Bax and Bcl-2 with respect to their relation to microcracks (Figure
10).
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Figure 10. Schematic diagram approximating osteocyte expression ofBax and 8cl-2 as a function of distance from a
microcrack. The gray area represents the hypothetical ~ 700 /lm radius of the effective osteonal area calculated by
Maltin [2]. Bax diminishes to zero over a distance of about 4 nun. Bcl-2 approximately doubles over a distance of
1.5 nun away from the crack and then decreases to zero at 4 nun. The solid line suggests a net expression ofBax and
BcI-2, i.e., the difference between the Bax and Bcl-2 signals. (4)

By examining the graph it can be seen that cells exhibiting Bax, apoptotic cells, reside closest to
the microcrack with the density of such cells decreasing linearly toward zero over a distance of
about four mm. Conversely, the density of cells exhibiting Bcl-2 starts low nearer to the
microcrack and then doubles at a distance about 1.5 mm away from the crack. Then the
concentration of Bcl-2 drops linearly to zero at about 4 mm away from the crack. It was
concluded by Verborgt [4] that "targeting and guidance of bone resorption to sites of
microdamage may be caITied out not only by signals from apoptotic cells near damage sites, but
also by signals from surrounding cells expressing apoptosis-inhibiting gene products". These
observations show that healthy cells residing significant distances away from microcracks are
protected from apoptosis, and thus resorption, while cells nearer to microcracks are influenced to
undergo apoptosis and thus amplify the signal for resorption. The solid line in the figure shows
the relative values of Bax and Bcl-2 illustrating the protective and shielding nature of Bcl-2 as
one moves further from a microcrack. The shaded region in the figure depicts the 700 /.lm
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distance from a microcrack that can be accessed by a steered BMU. In this region the solid line
increases in magnitude as distance to the microcrack decreases, showing that Bax is the
dominant molecule influencing apoptosis of surrounding cells and signaling of BMUs.
The second question looks at the resolution between conflicting steering mechanisms of
microcracks and the dominant lines of force in bone. As previously discussed, an area of low
force develops in front of a tunneling BMU resulting in apoptosis of those osteocytes residing in
that area. The apoptosis of these osteocytes attracts osteoclasts which home in on the region of
apoptotic cells. When this apoptotic area in front of a BMU merges with the apoptotic region
surrounding a rnicrocrack, the osteoclasts are attracted to the center of the denser region of
apoptotic osteocytes. The BMU is drawn closer to the center of this area where lies the
microcrack. Thus, the target of the BMU shifts from the dominant line of force to the
microcrack, its associated array of apoptotic osteocytes, and the chemical gradient produced by
signaling molecules [2]. Once the BMU passes through the microcrack it will track back to the
local stress field as its osteoclasts are attracted to the dominant loading patterns in the bone.
Martin concluded that the direction of BMU advancement is dependent on alignment
with the principle stress directions and targeting the removal of damage [2]. The degree to which
the trajectory of a BMU is altered to seek out and remodel microdamage is dependent on the
ability of signals to attract a BMU's osteoclasts. Osteocytes and their messenger chemicals
released during apoptosis are integral to this observation.

Hypothesis
The goal of this thesis is to investigate the relationship between bisphosphonate
medications and the remodeling process to see if the remodeling-suppressing drugs have an
effect on BMU steering and movement ofBMUs. Measurements will be made on longitudinal
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sections of canine rib bones to determine the distance between fluorescently tagged bands of new
bone growth. These distances along with the known time between administrations of the
fluorescent labeling will yield the velocity of the BMUs as they tunnel through bone. Data from
Matt Allen's research group at the Indiana University School of Medicine along with
measurements taken on the longitudinal bone sections will be utilized to determine the effects of
bisphosphonates on BMU steering and BMU movement. Three hypotheses were formed from
the general objectives:
1.

Data will lend support to Martin's theory [2] that BMUs are steered towards
microcracks by demonstrating that tunneling BMUs have an effective resorption
area that is much greater than the actual area of an osteon.

2.

Bisphosphonates will have the effect of decreasing the calculated effective
resorption area of tunneling BMUs, and thus decrease their ability to steer, and
the decrease in the effective resorption area is correlated to dose concentration.

3.

Bisphosphonates will have the effect of reducing BMU tunneling velocity and
measured osteonal resorption area (in a dose dependent manner) thus effecting a
new equilibrium crack surface density, under the assumption of steady state
damage formation and removal.
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2. Materials and Methods
Experimental Design
Bone samples came from a 3-year study performed by the Indiana University School of
Medicine involving the daily administration of bisphosphonate drugs to skeletally mature
beagles [12, 13, 14]. All experimental procedures were approved by the Indiana University
School of Medicine Animal Care and Use Committee. Female beagles (1-2 years old, n = 36)
were confirmed to be skeletally mature (closed proximal tibia and lumbar vertebral growth plates
on X-ray) prior to the start of the study [12]. Treatment involved daily, oral doses of vehicle
(VEH, ImL/kg saline) or Alendronate (ALN, 0.2 or 1.0 mglkg; Merck, Rahway, NJ)
administered by syringe. The lower dosage (0.2 mg/kg) corresponds to clinical levels of
bisphosphonates used to treat postmenopausal osteoporosis while the larger dosage (1.0 mg/kg)
corresponds to bisphosphonate levels used to treat Paget's disease [13]. Both dose sizes were
prepared by mixing Alendronate in saline to produce a 0.05% (lower dose) and a 0.2% solution
(higher dose). In each preparation, a correction was used to account for the 16.4% moisture
content of Alendronate [12]. Dosing was performed each morning after an overnight fast and at
least two hours prior to feeding.
To label newly formed bone, calcein (5 mg/kg as a 3% solution) was intravenously
administered on a 2-12-2-5 labeling schedule preceding necropsy. The animals were killed by
intravenous injection of sodium pentobarbital (0.22 mg/kg Beuthanasia-D Special; Schering
Plough, Union, NJ[AUl]) [12]. Immediately after death, the midpoint of the ninth rib was
removed and saved in 70% ethanol for evaluation of microdamage. Also, an adjacent section of
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the ninth rib was saved in 10% neutral buffered formalin for dynamic histomorphometric
measurements.

Microdamage Analysis
In order to evaluate specimens for microdamage, bone samples were stained en bloc with
1% basic fuschin and then embedded undecalcified in methyl methacrylate [12]. Two bulk
stained samples per animal were used to assess microdamage using a semiautomatic analysis
system (Bioquant OSTEO 7.20.10; Bioquant Image Analysis, Nashville, TN) attached to a
microscope equipped with an ultraviolet light source (Nikon Optihot 2; Nikon, Tokyo, Japan).
The possibility of finding no microdamage in any given specimen was reduced by analyzing two
specimens per animal. Ultraviolet fluorescence was used to measure crack length (Cr.Le), crack
number (Cr.N), calculations of crack density (Cr.Dn, Cr.N/bone area), and crack surface density
(Cr.S.Dn, [Cr.N

* Cr.Le]/bone area) in the cortex of the rib [18]. All variables were measured

and calculated in accordance with American Society for Bone and Mineral Research
recommended standards [15]. Analysis was performed by Matt Allen's group at Indiana
University and results were obtained for subsequent calculations.

Sample Preparation
Bone samples were received embedded undecalcified in methyl methacrylate and stained
en bloc with 1% basic fuschin. Longitudinal sections were cut from each sample using a high
precision bone saw (Isomet 1000; Buehler Ltd., Lake Bluff, IL). After cutting, the sections were
sanded to a thickness of 100 micrometers using a sequence of 400 and 600-grit sandpaper and
then mounted on microscope slides (Eukitt Mounting Medium; Electron Microscopy Sciences,
Hatfield, PA).
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BMU Velocity Measurements
The velocity of resorbing BMUs, Y.BMU, was calculated by measuring the distance
between fluorescent calcein labels and dividing that distance by the time between subsequent
injections of calcein (labeling schedule). Slides were viewed using a fluorescent microscope
(Olympus BX41; Olympus, Center Valley, PA) and ultraviolet filter (31001 FITC; Chroma,
Rockingham, VT). The excitation and emission wavelengths of calcein are 495 and 520
nanometers respectively [16]. Calcein labels of new bone formation appear as parallel bright,
yellow lines under ultraviolet light. Pictures oflabeled BMUs were taken using imaging software
(QCapture Pro; QImaging, Surrey, BC, Canada) and imported into image processing and
analysis software (lmageJ; http://rsb.info.nih.govlijl). A ronchi ruling was used to calibrate the
length measurements taken using ImageJ. Measurements were made using the method of
Jaworski and Lok [17] on bone specimens from dogs receiving treatment for three years (Figures
11 and 12).
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a

Figure II. Double labeled BMUs under fluorescent microscope. In BMUs Band D the first and second labels are
marked as I and II respectively. (17)
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Figure 12. Schematic representation of a longitudinally sectioned BMU. The distance Q represents the distance the
BMU traveled between tetracycline labeling injections. (17)

Jaworski and Lok viewed BMUs under fluorescent microscopy and calculated the distance
between the end of the first fluorescent label and the end of the second fluorescent label (distance
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Q in Figure 12). This method was repeated for the current study as can been seen in Figures 13
and 14. Figures 15 and 16 show two more examples of double-labeled BMUs that were
measured in this study.
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Figure 13. Double-labeled, longitudinally sectioned BMU. The BMU was traveling to the left. Labeling injections
were given 12 days apart, where I represents the fIrst label and II represents the second label.

Figure 14. BMU in Figure 12 with arrows representing the distances measured to determine BMU velocity.

Figure 15. Double-labeled longitudinally sectioned BMU with arrows representing the distance measured between
labels for BMU velocity calculation.
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Figure 16. Double-labeled longitudinally sectioned BMU with alTows representing the distance measured between
labels for BMU velocity calculation.

The three treatment categories were control, low dose bisphosphonate (Alendronate 0.2 mg/kg
body weight), and high dose bisphosphonate (Alendronate 1.0 mg/kg body weight). At least
three double-labeled BMUs were located and measured for each longitudinally sectioned
specimen and the measurements were averaged to yield the average distance for each specimen.
The average distances for each specimen were divided by 12 (the number of days between
labeling injections) to determine BMU velocity. The average velocities for each of the 12
specimens in each treatment group were averaged to determine the overall average velocity for
each treatment group.

Histomorphometric Analysis
Measurements of mean crack length, Cr.Le, and mean BMU resorption cavity density,
Rs.Ar, for the rib sections were made by Allen et a1. and provided for further analysis. Using a
model created by Martin [2] to describe BMUs traveling through bone containing microcracks,
the cross-sectional area of a BMU can be calculated. According to Martin, in a section of bone
with area AT containing a crack with length

Lo, a BMU, with area ABMU , tunneling at random

through this section of bone will remove a fraction of the crack's length,

~L.

The portion of the
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crack removed by the BMU can also be defined as i1L/Lo= ABMU/AT and the total length of the
crack is then expressed by the following equation:
L = Lo - i1L = Lo(1 - i1L/ Lo) = Lo(1- ABMU/AT) [2]

(1)

If multiple BMUs, NR, all with the same area, A BMU , tunnel independently through the section of
bone at random locations so that none overlap, then the crack length absorbed by the BMUs
would be N R times as great and the above equation can be re-written:
L = Lo{ 1 - (NR ABMu)1AT} or L = Lo - ABMuLo(NR I AT) [2]

(3)

Changing to standard histomorphometric notation and noting that N R I AT is equal to the
resorption spaces per unit area, Rs.Ar, the above equation can be written in the following fonn:
Cr.Le = iCr.Le - (On.Ar x iCr.Le)Rs.Ar

(4)

Where Cr.Le is the mean crack length, iCr.Le is the mean initial crack length, and ABMu =
On.Ar, the cross-sectional area of individual osteons [2]. Taking values from multiple bone
specimens and graphing mean crack length (Cr.Le) with respect to mean resorption space density
(Rs.Ar) should yield a linear relationship for bone specimens where the slope divided by the
intercept is equal to the mean osteonal area, On.Ar, of a resorbing BMU. On.Ar represents the
"effective" osteonal area and may differ from actual calculated osteonal areas if the BMUs travel
toward and resorb microdamage that they wouldn't nonnally pass through. It is assumed that a
nonnally tunneling BMU will follow the predominant lines of force in a bone specimen and will
resorb whichever microcracks the BMU happens to encounter along that path. IfBMUs target
microdamage then they will veer off of their nonnal path to pursue microdamage lying within a
certain distance away from the guiding line of force before returning back to their original
heading. As the BMU constantly weaves through the bone matrix resorbing microdamage and
following the principal loading directions, its calculated effective osteonal resorption area will
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appear larger than its measured osteonal area. Three graphs were created in order to calculate
effective On.Ar for the three year study data consisting of a control bone treatment group, low
dose (0.2 mglkg) of Alendronate treatment group, and high dose (1.0 mglkg) of Alendronate
treatment group. Mean crack length and mean resorption space density data needed to perform
these calculations were provided by Allen et al. and can be seen in Table 1.

Analyzing Effect of Bisphosphonates
The effects ofbisphosphonates on microdamage targeting by BMUs were analyzed by
statistically comparing their calculated effective osteonal resorption areas. As discussed above,
the effective osteonal resorption areas were calculated for a control group, low dose
bisphosphonate group (Alendronate 0.2 mg/kg body weight), and a high dose bisphosphonate
group (Alendronate 1.0 mg/kg body weight). Significance between the groups was calculated to
determine if there is a relationship between bisphosphonate dose size and the size of the effective
osteonal resorption area. It is hypothesized that an increase in bisphosphonate dose corresponds
to a decrease in the effective osteonal resorption area because as bisphosphonates suppress the
action ofBMUs the ability of BMUs to steer towards microdamage will also be suppressed.
The effects of bisphosphonates were also explored in an analysis of BMU tunneling
velocity, osteonal area, and total crack length per unit area of bone cross-section. Assuming that
BMUs do not target microcracks, they will remove whatever damage they encounter and their
damage removal rate can be found by the following equation:
[d(Cr.S.Dn)/dt]removal = V.BMU x On.Ar x Cr.S.Dn

(5)

Where Cr. S.Dn is the total crack length per unit area of a bone cross-section (crack surface
density) and Y.BMU is the velocity of a tunneling BMU. This equation predicts that the crack
removal rate is directly proportional to V.BMU, On.Ar, and Cr.S.Dn and will increase or
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decrease with corresponding changes in the aforementioned variables. As the tunneling velocity
of a BMU increases, it logically follows that more microdamage will be encountered and
removed by the BMU. Introduction ofbisphosphonates is assumed to suppress the BMU
activation rate and subsequently decrease damage removal causing a decrease in tmmeling
velocity of BMUs and mean osteonal area. When damage formation and damage removal reach
equilibrium in bone, equation 5 implies that damage formation is equal to V.BMU x On.Ar x
Cr.S.Dn. This means that when Y.BMU and On.Ar decrease due to the presence of
bisphosphonates, Cr.S.Dn may increase until a new equilibrium is reached. Increased Cr.S.Dn
(Cr.S.Dn E, where the E stands for the new equilibrium value) may be expressed as:
E_

Cr.S.Dn T

[d(Cr.S.Dn)/ dt]/ormar;on
T

V.BMU x On.Ar

T

T

Where V.BMU and On.Ar are the decreased BMU velocity and mean osteonal area
respectively, caused by the administration of bisphosphonates. Y.BMU data was measured
following the methods described by Jaworski and Lok [17]. Cross-sections of bone specimens
were used to calculate mean On.Ar and Cr.S.Dn. Osteonal area and microcrack length and
number data were provided by Allen et al.

Statistics
To evaluate dependence of mean BMU velocity, mean osteonal area, and total crack
length per unit area of bone cross-section on bisphosphonate treatment, a one-way ANOVA
utilizing a Tukey posthoc comparison was performed using Minitab (Minitab Inc.; State College,
PA). P-values less than 0.05 were considered statistically significant and represented significant
difference between the treatment groups. The ANOVA was verified by performing a test for
equality of variance and normality for each data set. Equality of variance testing utilizing
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Levene's test statistic showed significance of equality for p > 0.05. Normality testing analyzed
the data set's residuals using the Anderson-Darling method which showed normality for p >
0.05.
T-test analysis was performed for the equilibrium crack surface density values to look for
equality between the equilibrium values and the measured values where the null hypothesis was
that the equilibrium crack surface density was equal to the measured crack surface density.
Similar analysis was also performed for the measured On.Ar values for the CON, ALNO.2 and
ALN1.0 treatments to see if the mean measured area was similar to the calculated effective
osteonal resorption area. For each test, the null hypothesis was rejected for p < 0.05.
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3. Results
Effective Osteonal Area
Using the equation developed by Martin [2]:
Cr.Le = iCr.Le - (On.Ar x iCr.Le)Rs.Ar

(1)

where Cr.Le equals mean crack length, iCr.Le equals mean initial crack length, On.Ar equals
mean osteonal area, and Rs.Ar equals mean resorption space density, data was taken from Allen
et al [12] and analyzed. See Table 1 for three year values of crack length and resorption space
density organized by treatment category. Twelve samples for each of the three treatment
categories - control, 0.2 mg/kg Alendronate, and 1.0 mg/kg Alendronate (CON, ALNO.2, and
ALNl.O respectively) - were measured by Allen et al. [12] to provide the data in Table 1.
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Table 1: 3 year data by treatment for crack length and resorption space density.

3 year
Sample #

Treatment

Cr.Le
(mm)

Rs.Ar
(mm 2)

59210
59211
59219
59230
59231
59234
59235
59236
59238
59239
59244
59256
59257
59258
59315
59536
59677
60592
60593
60628
60629
60630
60631
60632
60634
60636
60641
60642
60643
60644
60645
60657
60667
60707
60750
60809

CON
ALN1.0
ALNO.2
ALNO.2
ALN1.0
CON
ALNO.2
ALN1.0
ALN1.0
ALNO.2
ALN1.0
ALNO.2
CON
ALNO.2
CON
ALN1.0
CON
ALNO.2
ALN1.0
CON
ALNO.2
CON
ALNO.2
CON
CON
ALNO.2
ALN1.0
ALNO.2
ALN1.0
CON
ALNO.2
ALN1.0
CON
CON
ALN1.0
ALN1.0

0.04487
0.09284
0.07609
0.06811
0.09103

0.77256
0.67596
0.40838
0.71990
0.47557
0.12996
0.61030
0.77620
0.67416
0.65326
0.59295
0.61265
0.55057
0.88063
1.28135
1.02281
0.82046
0.38463
0.69665
0.15427
0.57732
0.68077
0.65338
0.29406
0.13583
0.15357
0.12191
0.22093
0.46634
0.74438
0.14696
0.63245
0.73417
0.00000
0.25834
0.25422

0.06926
0.06561
0.06971
0.06490
0.05488
0.06485
0.05847
0.07192
0.06880
0.06955
0.04754
0.06769
0.07078
0.06950
0.07447
0.08154
0.06957
0.07113
0.06506
0.07902
0.08264
0.07534
0.04548
0.08629
0.08190
0.06471
0.04920
0.05774
0.07237

Using the data in Table 1 and Martin's equation, crack length (Cr.Le) was graphed with respect
to resorption space density (Rs.Ar) for each treatment category as seen in Figures 16 - 18.
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Figure 17. Crack length graphed with respect to resorption space density for control (CON) treatment. Effective
osteona1 resorption area is calculated by dividing the magnitude of the slope by the y-intercept.
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Figure 18. Crack length graphed with respect to resorption space density for Alendronate 0.2 mg/kg (ALNO.2)
treatment. Effective osteonal resorption area is calculated by dividing the magnitude of the slope by the y-intercept.
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Figure 19. Crack length graphed with respect to resorption space density for Alendronate 1.0 mg/kg (ALNl.O)
treatment. Effective osteonal resorption area is calculated by dividing the magnitude of the slope by the y-intercept.

Martin's equation assumes that the data follows a linear relationship, the slope of the line of best
fit through the data represents the product of osteonal area and initial crack length, and the yintercept of the line of best fit represents the initial crack length. By dividing the slope of the line
of best fit by y-intercept and converting units to 11m in Figures 1 - 3, the effective osteonal area is
obtained. The effective osteonal area is then compared to the measured osteonal area for each
sample as displayed in Table 2.

Table 2: Effective osteonal resorption area and actual osteonal area by treatment

3 year
Treatment
CON
ALNO.2
ALN1.0

Effective
On.Ar (IJm 2)
1.783x105
1.441 x10 5
2.022 x104

Measured
On.Ar (IJm 2)
1.392 x104
1.135 x104
1.542x1Q4

The three year data shows an effective osteonal area of 1.783x 10 5 , 1.441 x10 5 , and 2.022x 104
11m2 for the CON, ALNO.2, and ALN1.0 treatments respectively. Measured osteonal areas for the
4

4

4

three year samples are 1.392x 10 , 1.135x 10 , and 1.542x 10 11m2 for the CON, ALNO.2, and
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ALN 1.0 treatments respectively. These effective areas correspond to osteonal diameters of
476.46,428.34, and 160.45 /lm for the CON, ALNO.2, and ALNl.O treatments respectively
while the measured osteonal areas cOiTespond to osteonal diameters of 133.14, 120.23, and
140.11 /lm with respect to the CON, ALNO.2, and ALNl.O treatments. The three year data shows
an effective osteonal area approximately 12.8 times as large as the measured osteonal area for the
CON group and an effective osteonal area approximately 12.7 times as large as the measured
osteonal area for the ALNO.2 treatment. The effective osteonal area is nearly similar to the
measured osteonal area for the ALN 1.0 treatment. The effective osteonal areas for the CON and
ALNO.2 treatments are an order of magnitude larger than the effective osteonal area for the
ALN 1.0 treatment.
BMU Velocity
BMU velocity calculations were made for the three year samples by measuring the
distance between double-labeled BMUs in longitudinal sections following the method of
Jaworski and Lok [17] and then dividing the length measurements by 12 - the number of days
between labeling injections. Velocity data for the three different treatments (CON, ALNO.2, and
ALNl.O) can be seen in Table 3.
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Table 3: BMU velocity, measured osteonal area, and crack surface density by treatment.
Sample
Number
59210
59211
59219
59230
59231
59234
59235
59236
59238
59239
59244
59256
59257
59258
59315
59536
59677
60592
60593
60628
60629
60630
60631
60632
60634
60636
60641
60642
60643
60644
60645
60657
60667
60707
60750
60809

Treatment
Group
CON
ALN1.0
ALNO.2
ALNO.2
ALN1.0
CON
ALNO.2
ALN1.0
ALN1.0
AL1'J0.2
ALN1.0
ALNO.2
CON
ALNO.2
CON
ALN1.0
CON
·ALNO.2
ALN1.0
COI'J
ALNO.2
CON
ALNO.2
CON
COI'J
ALNO.2
ALN1.0
ALNO.2
ALN1.0
COI'J
ALNO.2
ALN1.0
CON
CON
ALN1.0
ALN1.0

V.BMU
(IJm/day)
21.8000
23.1500
16.6400
14.1000
4.9700
26.8500
20.6200
7.3400
14.8500
23.9500
11.9800
34.5400
8.4500
12.7400
4.3900
10.0900
8.3600
5.4700
24.4100
10.8700
26.4500
15.9900
12.1100
21.9700
6.1200
7.8800
18.0700
4.8300
12.4600
14.8000
11.3500
18.6000
7.4000
21.9100
18.4600

Measured
On.Ar (~m2)

er.S.On
(IJm/mm 2)

12671.280

10.074
15.485
84.403
14.251
67.963

12529.640
9261.140
17875.933

6723.558

9918.595
11499.070
17174.090
9570.580

19004.800
12011.710
13245.650
15310.070
25273.850
10365.970
15748.200
10553.058

37.743
29.717
32.326
34.229
7.933
19.804
26.958
41.581
38.130
50.578
9.740
74.703
62.150
83.539
23.732
91.402
5.515
66.902
10.352
80.388
48.916
34.993
15.682
57.832
48.304
4.614
11.845
28.786
30.544

Average BMU velocity is 19.12, 14.16, and 11.33 I-un/day for the CON, ALNO.2, and ALN1.0
treatments respectively (Table 4).
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Damage Formation
Table 3 also contains measured osteonal area (On.Ar) and crack length per unit area of
bone cross-section (CLS.Dn) data. Osteonal area and crack density measurements are provided
by Matt Allen et al. BMU velocity, osteonal area and crack density are related to BMU damage
removal by the following equation:
[d(Cr.S.Dn)/dt]removal = V.BMU x On.Ar x Cr.S.Dn.

(2)

Using the values from Table 3, the rate of damage removal for the control specimens is found to
be 6605.66 Ilm2/day. Making the assumption that in a steady state situation damage removal is
equal to damage fonnation, damage formation is also equal to 6605.66 Ilm2/day. Under
treatment, with changing values ofY.BMU and On.Ar, a new equilibrium crack surface density
will be reached that is represented by the following equation:
E _

Cr.S.Dn -

[d(Cr.SDn)/ dt]/ormo,ion
T

V,SMU x On.Ar

(3)

T'

Average values for the V.BMU, On.Ar, and Cr.S.Dn data present in Table 3 are shown below in
Table 4.

Table 4: Average BMU velocity, average measured osteonal area, and average crack surface
density by treatment.
Treatment
Group

Ave. V.BMU
(lJm/day)

Ave. Measured
On.Ar (~m2)

Ave. er.S.On
2
(lJmtmm )

CON

19.118

13922

24.818

ALNO.2

14.163

11352

44.912

ALN1.0

11.327

15418

40.764

Using equation 3 and the damage fonnation rate determined for the control group, an equilibrium
crack surface density was calculated for both the ALNO.2 and ALNI.O groups. For the ALNO.2
and ALNO.1 treatments, the equilibrium crack surface density is 41.086 and 37.822 Ilm/mm2
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respectively. Measured Cr.S.Dn values are 44.912 and 40.764 flmlmm2 for the ALNO.2 and
ALN1.0 treatments respectively as seen in Table 4.

Statistics
An ANOVA was performed to explore the relationship between actual osteonal area,
BMU velocity, and crack surface density with respect to the three treatment groups. Results are
found in Table 5 for the ANOVA using a Tukey posthoc comparison.

Table 5: ANOVA results for BMU velocity, measured osteonal area, and crack surface density
by treatment

V.BMU (J-Im/day)
Measured On.Ar

(J-Im

2

CON

ALNO.2

ALN1.0

p

19.18±8.25

14.16 ± 5.3

11.33±7.13*

0.036

13922 ± 2940

11352 ± 4185

15418 ± 6134

0.338

24.82 ± 27.38

44.91 ± 27.27

40.76 ± 21.56

0.157

)

Measured Cr.SDn

(J-Im/mm

2

)

Data are mean ± SD. P values refer to a one-way ANOVA among the three groups:

* vs. CON

Individual p values for each Tukey comparison for measured On.Ar and Cr.S.Dn were all greater
than 0.05 which is reflected in the overall p value reported in Table 5. The p values for the
individual Tukey comparisons performed for BMU velocity are presented in Table 6.

Table 6: P values for individual Tukey comparisons for BMU velocity one-way ANOVA

Comparisons

P

CON and ALNO.2

.0922

CON and ALN1.0

.0119

ALNO.2 and ALN1.0

.3387

The ANOVA was verified by checking for equality of variance and normality for each data set.
Equality of variance testing utilizing Levene's test statistic showed significance of equality for p
> 0.05. Normality testing analyzed the data set's residuals using the Anderson-Darling method
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which showed normality for p > 0.05. See Figures 19,20, and 21 for graphical representation of
the tests for equality of variance and normality.
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The normality test for Cr.S.Dn has p < 0.05 which would usually signify a failure of normality
but the deviations from normality, in this case, won't interfere with the conclusions drawn from
the ANOVA of the Cr.S.Dn data. A clustering of data points in the Cr.S.Dn data set is causing
the failure, but this clustering can be overlooked as inconsequential due to the nature of the data
thus the ANOVA is valid [19]
T-test analysis was performed for the equilibrium crack surface density values to look for
equality between the equilibrium values and the measured values. Similar analysis was also
performed for the measured On.Ar values for the CON, ALNO.2, and ALNI.O treatments to see
if the mean measured area was similar to the calculated effective osteonal resorption area.
Beginning with the ALNl.O treatment area calculations, it was found through a one-sample t-test
analyzing the measured On.Ar data, that the mean of the On.Ar data was similar to the calculated
effective area with p = 0.155. The null hypothesis, that the mean of the On.Ar data was the same
as the calculated effective area, was not rejected because p > 0.05 and the effective osteonal area
is statistically similar to the measured osteonal area for the ALNI.O treatment. T-tests for the
CON and ALNO.2 groups showed that there was a significant difference between the effective
osteonal area and the measured actual osteonal area. P values for these t-tests were both less than
0.001 resulting in a rejection of the null hypothesis. With respect to equilibrium crack surface
density, the null hypothesis being tested was that the mean measured crack surface density was
the same as the calculated equilibrium crack surface density for the ALNO.2 and ALNl.O groups.
T-test results yield p values greater than 0.05 for both the ALNO.2 and ALNI.O groups. Thus it
can be assumed that the equilibrium crack surface density values are equal to the mean measured
crack surface density for both the ALNO.2 and ALNI.O treatments.
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4. Discussion
The objective of this study was to investigate the relationship between long-term
bisphosphonate use (3 years), microdamage targeting by BMUs, BMU velocity, and crack
density in canine rib bones. The canine model was selected for this study because the remodeling
dynamics appear to be similar between human and canine cortical bone [17]. Bisphosphonate
doses used in this research were administered on a milligram per kilogram of body weight basis
in order to parallel common dosage levels used to treat postmenopausal osteoporosis in the
clinical setting. Canines are also suitable for studies involving bone remodeling dynamics
because they show evidence of osteocyte apoptosis and microcrack accumulation. The
hypotheses under investigation are as follows: 1) BMUs are drawn toward microdamage in the
bone matrix and effectively steer towards microcracks as they tunnel through bone along the
dominant lines of force present in bone, 2) Bisphosphonates will have the effect of decreasing
the calculated effective resorption area ofBMUs, and thus decrease their ability to steer, in a
dose dependent manner, and 3) Bisphosphonates will reduce the tunneling velocity and actual
osteonal area ofBMUs thus effecting a new equilibrium crack surface density, under the
assumption of steady stage damage formation and removal. Data comes from samples supplied
by Allen et al. [12] from the Indiana University School of Medicine. This study is unique in that
it combines the canine rib model with bisphosphonate treatment spanning a three year time
period. Previous long-term studies focused on vertebral remodeling or lasted one year [13, 14,
20,21,22,23].
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Microdamage Targeting
The three year study data supports the hypothesis that BMUs target microdamage and are
steered by microcracks in the bone matrix. For two of the treatments (CON and ALNO.2) the
calculated effective osteonal area is greater than the measured osteonal area. Following Martin's
study [2], the results support his assertion that BMUs are drawn towards microcracks as they
tunnel through bone following the dominant lines of force. In the case of the control group, the
effective osteonal area is approximately 12.8 times as large as the measured osteonal area. At
1.39xl04 11m2, the measured osteonal area is 7.8% of the 1.78x10 5 11m2 value derived from
Martin's equations. The effective osteonal area corresponds to an effective osteonal diameter of
476 11m, which is significantly larger than the 120 ± 28 Jlm range predicted by Jaworski and Lok

[17] for BMUs in canine cortical bone and the 150 to 220 Jlm range predicted by Moyle and
Bowden [11] for BMUs in human cortical bone. The ALNO.2 treatment group also shows an
increased effective osteonal area compared to the measured value. The lower dose Alendronate
treatment (ALNO.2) exhibits an effective osteonal area of I.44xl051lm while the measured
4
osteonal area is I.I4x 10 /lm, and the higher dose Alendronate treatment (ALN 1.0) exhibits an
effective osteonal area of2.02x1041lm while the measured osteonal area is 1.54x104 11m. For the
ALNO.2 treatment, the measured osteonal area is 8% of the effective area value and yields an
effective osteonal area that is greater than the measured osteonal area. Statistical analysis shows
that the calculated effective osteonal area is significantly similar to the measured osteonal area
for the ALN 1.0 treatment indicating that microdamage targeting does not occur for the high dose
Alendronate treatment. Only the CON and ALNO.2 treatment groups support the hypothesis that
BMUs target and steer towards microdamage as they tunnel through bone during the remodeling
process. These findings also support the assertions made by Burr that about 30% of bone

43

remodeling is targeted to the repair of microdamage [24]. The larger-than-measured effective
osteonal areas demonstrate that BMUs are straying from their trajectories along the principle
loading directions in bone to seek out microdamage. Although Burr's hypothesis regarding
targeted repair of microdamage has yet to be experimentally or computationally proven, the
present data lends support to the idea that remodeling targets microdamage.
The second hypothesis is addressed by observing the relationship between the effective
osteonal area and bisphosphonate dosage. The presence of bisphosphonates seems to have a
suppressive effect on the effective osteonal area. Li et al. [20] found that bisphosphonate
treatment suppressed both targeted and nontargeted (stochastic) remodeling along with targeted
repair of microdamage. Li's study administered both Risedronate and Alendronate
bisphosphonates to skeletally mature beagles and assessed the association between cracks and
resorption spaces. The study observed that there were fewer cracks associated with resorption
spaces than expected in the Risedronate and Alendronate groups indicating that both targeted and
non-targeted remodeling are suppressed. Their findings are supported by current results in that
the calculated effective osteonal area of the ALN1.0 group is observed to decrease from that of
the control group's. As stated above, the effective osteonal area of the CON group was 12.8
times larger than the measured area while the effective osteonal area of the ALN 1.0 group was
statistically similar to the measured area. In addition, the effective osteonal area for the CON
group was a factor of 10 larger than that for the ALNl.0 treatment group. Bisphosphonate
treatment at the high dose level caused a decrease in the ratio of effective osteonal area to actual
osteonal area with respect to the CON and ALN 1.0 groups. The difference in the ratio of
effective osteonal area to actual osteonal area with respect to the CON and ALNO.2 groups was
less decisive. The effective osteonal area calculated for the ALNO.2 group was 12.7 times as
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large as the actual osteonal area while the effective area for the CON group was 12.8 times as
large as the actual osteonal are. Statistical analysis shows that for both the CON and ALNO.2
groups, the calculated effective area is significantly different that the measured osteonal area.
The ALNO.2 treatment seems to have little suppressive effect on the effected area while the

ALNI.O seems to have a large suppressive effect on the effective area. This observation was
most likely the result of the dosage level of the bisphosphonate treatment. The data seems to
indicate that suppression of the effective osteonal area doesn't occur at the lower bisphosphonate
dose level but requires a dose approximately five times higher than clinical osteoporosis
treatment levels to achieve the suppressive effect. This suppressive action is expected since the
action ofbisphosphonates is to inhibit BMU activation and the ability of osteoclasts to absorb
bone. If the ability of osteoclasts to tunnel through bone is inhibited, then they won't be as able
to steer towards microdamage. Suppressing BMUs in such a way decreases their effectiveness
during remodeling and explains the decrease in effective resorption area seen in this study. These
results support the hypothesis that bisphosphonates suppress the microdamage targeting ability
of BMUs in a dose dependent marmer. As mentioned above, one-sample t-test statistical analysis
comparing the effective osteonal area to the measured osteonal area determined that the effective
area for both the CON and ALNO.2 differ from the measured, actual osteonal area. The null
hypothesis for the one-sample t-test is that the mean measured osteonal area is equal to the
effective osteonal area. P values for the analysis involving the CON and ALNO.2 treatments were
below 0.05 resulting in the rejection of the null hypothesis. T-test results for the ALNl.O
treatment led to the conclusion that the effective and measured areas do not different from each
other. These results support the second hypothesis of this study and show that the effective
osteonal resorption area is diminished with increased dose ofbisphosphonate treatment. In
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regards to BMU targeting of microdamage, it is implied that a decreased effective osteonal
resorption area results in decreased ability to steer towards microdamage. The data showing that
the effective area of the ALN 1.0 treatment doesn't differ from the measured area further
illustrates the decreased ability of BMUs to steer towards microdamage while under
bisphosphonate treatment. Ifbisphosphonates didn't have an effect on BMU steering, it is
expected that the effective osteonal area would match the CON group value in experimentation
involving any dose of bisphosphonate treatment.

Actual Osteonal Area
Contrary to this observation of suppressed effective osteonal area, the measured osteonal
area is similar between all three experimental groups. Even though targeted remodeling is being
suppressed by bisphosphonate treatment, the actual resorption area of active osteons remains at
normal values. Statistical analysis reveals that the mean measured osteonal areas are statistically
similar for the CON, ALNO.2, and ALNl.O treatments. While it was hypothesized that actual
osteonal area would decrease with bisphosphonate use this is clearly not the case. The hypothesis
was formed based on research examining the suppressive affects ofbisphosphonates on the
remodeling process. It was thought that inhibited BMUs would be unable to form osteons of
normal size due to the inability of osteoclasts to properly resorb bone. Osteoclasts would be less
effective at creating normal sized resorption cavities which would result in osteons with lower
than normal areas after bone formation by osteoblasts. The analysis perforrn.ed in this study
refutes the hypothesis that bisphosphonate treatment reduces actual osteonal area in a dose
dependent manner since the measured osteonal areas were shown to be statistically significant
among all three treatment groups.
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BMU Velocity
In a three year study by Allen et al. the toughness of bone was analyzed in relation to

bisphosphonate treatment and microdamage accumulation. Under Alendronate treatment, bone
toughness decreased without an overall accumulation of microdamage [12]. Bisphosphonate
doses mirrored doses given in the present study, and significant losses in toughness were noted
only for the ALNl.0 treatment group [12]. This result seems to parallel the decrease in the
effective osteonal area calculated in the present study in that only the higher dose of
bisphosphonate treatment has an effect on the scrutinized property. Across all three treatment
groups in Allen's study (CON, ALNO.2, and ALNI.O) there was no significant difference in
overall microdamage accumulation. Taking Allen's work a step further, the effect of
bisphosphonate treatment on BMU velocity was explored in the study presented here. Average
velocities for the 12 samples in the CON, ALNO.2, and ALNl.O treatments were 19.12, 14.16,
and 11.33 !-un/day respectively. Analysis revealed no significant difference in the average
velocity for the CON and ALNO.2 treatments. Conversely, a significant difference in the average
velocities of the CON and ALNl.O groups was noted. Analysis comparing BMU velocity for the
ALNO.2 and ALNl.0 groups reveals that they are statistically similar. It can be reasoned that
high dose bisphosphonate treatment decreases BMU velocity by observing the significant
difference between the CON and the ALNl.O treatment groups. The lack of significance in
velocity differences between the CON and ALNO.2 treatments may be due to a threshold effect
with respect to bisphosphonate dose level. There may be a critical dosage level that once
surpassed causes a significant decrease in BMU velocity from the control like that seen for the
ALNl.0 treatment. The significance of the decrease in average velocity between the CON and
ALNl.O treatments shows a suppressive effect ofbisphosphonate treatment at high dose levels.

47

Crack Surface Density
As part of the analysis of Allen et al. on the effects of bisphosphonates on bone toughness
and microdamage accumulation [12], mean crack length, crack number, and crack surface
density were calculated. Utilizing mean crack length, crack number, and crack surface density,
Allen et al. [12] concluded that there were no significant differences in overall microdamage
accumulation between the CON, ALNO.2, and ALNl.0 treatments although mean crack length
was higher in both the ALNO.2 and ALNl.O groups compared to the CON group [12]. The
present study furthers the analysis of Allen et al. [12] by validating a model to predict
equilibrium crack surface density values in an assumed steady state condition with respect to
damage formation and removal. The third hypothesis is evaluated using the average values of
BMU velocity, actual osteonal area, and crack surface density for the CON group to calculate the
steady state value of damage formation and removal following the equations:
[d(Cr.S.Dn)/dt]removal = Y.BMU x On.Ar x Cr.S.Dn
E

Cr.S.Dn =

[d (Cr.S.Dn) / dt] formation
V.BMU

T
X

On.Ar

T'

(1)
(2)

In equations (1) and (2), Y.BMU equals BMU velocity, On.Ar equals measured osteonal area,
Cr.S.Dn equals crack length per unit area of bone cross-section, Cr.S.Dn E equals equilibrium
crack surface density, V.BMU T equals the BMU velocity under treatment, On.ArT equals the
osteonal area under treatment, and [d(Cr.S.Dn)/dt]removal and [d(Cr.S.Dn)/dt]formation equal damage
removal and formation respectively. At steady state with respect to the remodeling process, it is
assumed that due to normal BMU activity, the amount of damage formed in the bone matrix is
equal to the amount of damage removal by the remodeling process. Using the steady state
damage formation value and dividing by the treatment values of BMU velocity and actual
osteonal area an equilibrium crack surface density was calculated for both the ALNO.2 and
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ALN1.0 treatments. Equilibrium crack surface density values were 41.086 and 37.822 Ilm/mm2
for the ALNO.2 and ALN1.0 treatments respectively. The measured values of crack density were
44.912 and 40.764 Ilm/mm2 for the ALNO.2 and ALN1.0 treatments respectively. Statistical
analysis comparing the calculated equilibrium values to their corresponding measured values
showed no significant difference in the values. This conclusion supports the third hypothesis by
validating the steady state crack density model. The equilibrium crack surface density values are
equal to the measured crack surface density values as predicted, thus verifying equation (2). As
Y.BMU decreases, On.AT and [d(Cr.S.Dn)/dt]formation remain the same under treatment and the
equilibrium crack surface density should increase above the control value. Statistical analysis
determined that there is no significant difference in measured mean crack surface density
between the control and Alendronate treatments. Current crack surface density data fails the
Anderson-Darling normality test (p < 0.05), but the deviations from nOimality, in this case,
won't interfere with these conclusions because of the insignificant clustering effect of the data
[19]. It follows logically that as bisphosphonate treatment inhibits the remodeling process, the
crack surface density will increase as damage accumulates until a new equilibrium is reached
between damage formation and damage removal. This conclusion is supported by research
performed by Allen and colleagues in a study where crack surface density was seen to increase
over control values with the administration ofbisphosphonates for a one year time frame [14].
Allen's one year study [14] analyzing the microdamage accumulation in canine vertebral bone
found that crack surface density increased across all the Alendronate doses (ALNO.l, ALNO.2,
ALN1.0) compared to the control group. The doses of bisphosphonates used in the study
correspond to clinical treatment levels for postmenopausal osteoporosis, half that value, and five
times that value (used to treat Paget's disease). Allen also noted that although bisphosphonate
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treatment allowed significant microdamage accumulation in the vertebra, the detrimental effects
were offset by increases in bone volume and mineralization such that there was no significant
impairment of mechanical properties [14]. A later study by Allen and Burr examined the damage
accumulation effects of bisphosphonates on canine vertebra over a three year period and
compared the data to one year findings [13]. They concluded that while three years of
Alendronate treatment resulted in higher vertebral microcrack density (#/mm2) than for one year
of treatment, the amount of microdamage accumulation (determined by crack surface density,
l.unlmm

2

)

was not significantly different than the one year Alendronate treatment [13]. Allen and

Burr reasoned that damage accumulation due to bisphosphonate use occurs early in treatment so
there is little further damage seen after this period. Crack surface density in vertebral bone
reported by Allen and Burr was not significantly different among the treatment groups. The
current study's results seem to parallel Allen and Burr's findings as the steady state model
predicts that equilibrium crack surface density is similar to measured values for both the ALNO.2
and ALN1.0 treatments over a three year period. Present data also supports and confirms Allen
and Burr's results that there was no significant difference in crack surface density among
treatment groups as seen from the results of the previously mentioned one-way ANOVA
showing that there is no significant difference comparing measured crack surface density
between the CON, ALNO.2, and ALNl.O treatment groups.

Conclusions
This experimental study examined the theory of microdamage targeting by BMUs and
evaluated the effects of bisphosphonate treatment on remodeling dynamics. The results and
analysis aid in the understanding of the effective osteonal resorption area that is a result ofBMU
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steering. Data analysis also shows the dose dependent nature of bisphosphonates on remodeling
dynamics. The main conclusions to be drawn from this study are reported below:
1. Current research has shown that BMU steering is a highly plausible
explanation for targeted remodeling. Work done by Martin [2], conceming the
calculation of an effective osteonal resorption area that is greater than the
measured osteonal resorption area, is supported by this experimental study.
2. Bisphosphonates are seen in multiple studies to decrease the occurrence of
bone remodeling thus allowing the accumulation of microdamage [12, 13, 14,
20,22,23]. While suppressing the remodeling process, bisphosphonates also
suppress the ability of BMUs to steer towards microdamage as seen in the
dose dependent decrease of effective osteonal resorption area.
3. Bisphosphonates also have a suppressive nature in regard to remodeling
dynamics and decrease BMU tunneling velocity while leaving the actual
osteonal area unaffected.
4. An extrapolation of Martin's model describing the effective resorption area of
BMUs successfully shows that the new steady state equilibrium condition in
damage removal and formation achieved under bisphosphonate treatment is a
valid predictor of crack surface density.
5. Mean crack surface density for all three treatment groups (CON, ALNO.2, and
ALN1.0) is not significantly different which supports results in previous
studies examining the effects of bisphosphonate treatment on the remodeling
process [12, 13].
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Recommendations for Future Work
Currently, postmenopausal osteoporosis is a major disease affecting a majority of older
women. While predominantly diagnosed in women, osteoporosis also affects older men. The
main treatment for this disease is bisphosphonate medication meant to depress the remodeling
process in order to halt bone loss. To date, the effects of long term bisphosphonate treatment in
humans are not fully understood and complications involving microdamage accumulation may
exist that outweigh the risk of fracture encountered when not taking bisphosphonate drugs. More
long term studies concerning fracture risk associated with bisphosphonates are needed to better
quantify the benefits of bone remodeling suppressing drugs.
There are many present theories that offer explanations for the activation and movement
ofBMUs as they tunnel through bone. The model explored in this study focuses on BMU
steering by microcracks present in the bone matrix. Further studies that explore the effective
resorption area demonstrated by Martin [2] can be used to add support or refute his theory. After
observing the effects of microcracks on the effective resorption area of BMUs it would be
beneficial to correlate osteocyte apoptosis or osteocyte signaling to explore their relationship to
BMU steering.
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